<DOC>
	<DOCNO>NCT01599234</DOCNO>
	<brief_summary>The purpose study assess efficacy Sativex relieving symptom spasticity multiple sclerosis</brief_summary>
	<brief_title>A Study Evaluate Efficacy Sativex Relieving Symptoms Spasticity Due Multiple Sclerosis</brief_title>
	<detailed_description>This 15 week ( one week baseline fourteen week treatment period ) , multicentre , double blind , randomise , placebo control , parallel group study evaluate efficacy Sativex subject symptoms spasticity due multiple sclerosis . Eligible subject enter seven day baseline period . Subjects return centre randomisation dose introduction . Visits occur end treatment week two , six , ten end study ( treatment week 14 ) early withdrew .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Willing able give inform consent . Aged 18 year . Ability ( investigator 's opinion ) willingness comply study requirement . Diagnosed disease subtype multiple sclerosis duration great six month . Diagnosed spasticity due multiple sclerosis least three month duration wholly relieve current therapy . Stable dose antispasticity nonpharmacological therapy least 30 day prior screen visit willingness maintain duration study . Stable dose disease modify medication least six month duration prior screen visit willingness maintain duration study . The last six daily diary spasticity numerical rating scale score randomisation complete sum least 24 . Agreement responsible authority ( applicable individual country ) , primary care physician , consultant , appropriate , notified participation study . Concomitant disease disorder symptom spasticity , may influence subject 's level spasticity . Received Botulinum Toxin injection within four month prior screen visit unwillingness stop receiving Botulinum Toxin injection relief spasticity duration study . Had use cannabis within 30 day study entry unwillingness abstain duration study . Had use cannabinoid base medication within 60 day study entry unwillingness abstain duration study . History schizophrenia , psychotic illness , severe personality disorder significant psychiatric disorder depression associate underlying condition . Known suspected history alcohol substance abuse . History epilepsy recurrent seizure . Known suspect hypersensitivity cannabinoids excipients study medication . Experienced myocardial infarction clinically relevant cardiac dysfunction within last 12 month cardiac disorder , opinion investigator would put subject risk clinically relevant arrhythmia myocardial infarction . QT interval &gt; 450 m ( male ) &gt; 470 m ( female ) Visit 1 . Secondary tertiary arterial ventricular block sinus bradycardia ( heart rate &lt; 50 bpm ) sinus tachycardia ( heart rate &gt; 110 bpm ) Visit 1 . Diastolic blood pressure &lt; 50 mmHg &gt; 105 mmHg sit position rest 5 minute prior randomisation . Impaired renal function i.e . serum creatinine clearance lower 50 ml/min Visit 1 . Significantly impaired hepatic function , Visit 1 , investigator 's opinion and/or liver function test equal great three time upper limit normal . Female subject child bear potential male subject whose partner child bear potential , unless willing ensure partner use effective contraception study three month thereafter . If female , pregnant lactating , plan pregnancy course study three month thereafter . Received IMP within 12 week Visit 1 . Any significant disease disorder , opinion investigator , may either put subject risk participation study , may influence result study , subject 's ability participate study . Following physical examination , subject abnormality , opinion investigator , would prevent subject safely participate study . Scheduled elective surgery procedure , require general anaesthesia study . Intention donate blood study . Intention travel internationally study . Previous randomisation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>